Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · Real-Time Price · USD

239.00

-1.08 (-0.45%)

At close: Aug 26, 2026, 4:00 PM EDT

238.18

-0.82 (-0.34%)

After-hours: Aug 26, 2026, 7:47 PM EDT

Alnylam Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	4,804	3,714	2,248	1,828	1,037	844.29
Revenue Growth	95.14%	65.19%	22.97%	76.23%	22.88%	71.31%
Cost of Revenue	977.45	681.87	323.37	310.41	168.82	140.14
Gross Profit	3,827	3,032	1,925	1,518	868.6	704.14
Selling, General & Admin	1,318	1,211	975.53	795.65	770.66	620.64
Research & Development	1,509	1,320	1,126	1,004	883.02	792.16
Operating Expenses	2,827	2,530	2,102	1,800	1,654	1,413
Operating Income	999.78	501.58	-176.89	-282.18	-785.07	-708.65
Interest Expense	-284.2	-252.63	-141.86	-121.22	-155.97	-143.02
Interest & Investment Income	110.05	111.47	121.99	95.56	24.81	1.58
Other Non Operating Income (Expenses)	-55.91	-34.96	-177.6	-108.74	-100.86	-57.75
EBT Excluding Unusual Items	769.72	325.46	-374.35	-416.57	-1,017	-907.84
Gain (Loss) on Sale of Investments	-3.43	-2.31	-3.02	-16.94	-33.31	55.7
Other Unusual Items	-	-	-	-	-76.59	-
Pretax Income	766.29	323.15	-377.38	-433.52	-1,127	-852.14
Income Tax Expense	-8.42	9.41	-99.22	6.73	4.16	0.68
Net Income	774.71	313.75	-278.16	-440.24	-1,131	-852.82
Net Income to Common	774.71	313.75	-278.16	-440.24	-1,131	-852.82
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	133	131	128	125	122	118
Shares Outstanding (Diluted)	139	135	128	125	122	118
Shares Change	7.12%	5.51%	2.20%	2.64%	2.73%	3.01%
EPS (Basic)	5.84	2.39	-2.18	-3.52	-9.30	-7.20
EPS (Diluted)	5.62	2.33	-2.18	-3.52	-9.30	-7.20
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	819.87	465.38	-42.59	41.95	-613.33	-718.07
Free Cash Flow Per Share	5.91	3.46	-0.33	0.34	-5.04	-6.06
Gross Margin	79.65%	81.64%	85.62%	83.02%	83.73%	83.40%
Operating Margin	20.81%	13.51%	-7.87%	-15.43%	-75.68%	-83.94%
Profit Margin	16.13%	8.45%	-12.37%	-24.08%	-109.04%	-101.01%
Free Cash Flow Margin	17.07%	12.53%	-1.89%	2.29%	-59.12%	-85.05%
EBITDA	1,055	557.24	-120.22	-228.12	-740.6	-661.09
EBITDA Margin	21.95%	15.00%	-5.35%	-12.48%	-71.39%	-78.30%
D&A For EBITDA	54.76	55.66	56.67	54.05	44.47	47.57
EBIT	999.78	501.58	-176.89	-282.18	-785.07	-708.65
EBIT Margin	20.81%	13.51%	-7.87%	-15.43%	-75.67%	-83.94%
Effective Tax Rate	-	2.91%	-	-	-	-
Revenue as Reported	4,804	3,714	2,248	1,828	1,037	844.29
Advertising Expenses	-	36	29.7	12.4	11.7	-

SEC Filings: 10-K · 10-Q